NCT07116733 Desflurane vs. Propofol for Cardiac Anesthesia
| NCT ID | NCT07116733 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Xijing Hospital |
| Condition | Cardiac Surgery |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,560 participants |
| Start Date | 2025-10-20 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 3,560 participants in total. It began in 2025-10-20 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To investigate whether the inhaled anesthetic desflurane, compared with propofol, exerts cardioprotective effects and reduces the incidence of severe postoperative major cardiac events in patients undergoing coronary artery bypass graft (CABG) surgery.
Eligibility Criteria
Inclusion Criteria: 1. Patients scheduled for elective coronary artery bypass grafting (CABG) 2. Age ≥ 18 years old; 3. Sign the informed consent form. Exclusion Criteria: 1. Emergency or urgent operation 2. Concomitant valve or aortic surgery 3. History of myocardial infarction in recent 30 days 4. Current use of myocardial preconditioning-affecting medications, such as sulfonylurea (glibenclamide), allopurinol, theophylline, nicorandil(last dose \< 8 hrs), etc 5. Participated in other randomized controlled clinical trials in recent 3 months 6. General anesthesia in recent 30 days 7. History of kidney and liver transplantation, or severe liver and kidney dysfunction (EGFR ≤ 20 mlgmin/1.73 m2, conventional dialysis or patients who have started dialysis; Child Pugh grade C/cirrhosis) 8. History of open heart surgery; 9. Hemodynamic instability or severe heart failure (SBP\<90 mmHg or preoperative need of high-dose vasoactive drug support, placement of aortic balloon pump (IABP), ECMO or ventricular assist device, left ventricular ejection fraction\<30%) 10. Adverse drug reactions to trial medications 11. History of malignant hyperthermia 12. Pregnancy or lactation
Contact & Investigator
Chong Lei, M.D., phd
PRINCIPAL INVESTIGATOR
Xijing Hospital
Frequently Asked Questions
Who can join the NCT07116733 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiac Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07116733 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 3,560 participants.
Is NCT07116733 currently recruiting?
Yes, NCT07116733 is actively recruiting participants. Contact the research team at crystalleichong@126.com for enrollment information.
Where is the NCT07116733 trial being conducted?
This trial is being conducted at Fuzhou, China, Cangzhou, China, Shijiazhuang, China, Shijiazhuang, China and 10 additional locations.
Who is sponsoring the NCT07116733 clinical trial?
NCT07116733 is sponsored by Xijing Hospital. The principal investigator is Chong Lei, M.D., phd at Xijing Hospital. The trial plans to enroll 3,560 participants.